ETF Performance: The First Trust NASDAQ Pharmaceuticals ETF (FTXH) has reached a 52-week high, increasing 37.2% from its low of $23.29/share, attracting investor interest for potential momentum.
Market Drivers: The pharmaceutical sector is experiencing a resurgence due to favorable regulatory changes, improved funding conditions from Fed rate cuts, and the growing integration of AI in healthcare.
ETF Ranking and Outlook: FTXH holds a Zacks ETF Rank #3 (Hold) and shows a positive weighted alpha of 21.53, suggesting the possibility of continued strong performance in the near term.
Additional Resources: Zacks Investment Research offers a free newsletter with actionable insights and top-performing ETFs, along with a report on the "7 Best Stocks for the Next 30 Days."
Wall Street analysts forecast FTXH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FTXH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast FTXH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FTXH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 33.958
Low
Averages
High
Current: 33.958
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
